SG10201913573UA - Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins - Google Patents

Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Info

Publication number
SG10201913573UA
SG10201913573UA SG10201913573UA SG10201913573UA SG10201913573UA SG 10201913573U A SG10201913573U A SG 10201913573UA SG 10201913573U A SG10201913573U A SG 10201913573UA SG 10201913573U A SG10201913573U A SG 10201913573UA SG 10201913573U A SG10201913573U A SG 10201913573UA
Authority
SG
Singapore
Prior art keywords
type
compositions
methods
chimeric proteins
extracellular domains
Prior art date
Application number
SG10201913573UA
Inventor
Taylor Schreiber
George Fromm
Silva Suresh De
Neal SCHILLING
Original Assignee
Heat Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heat Biologics Inc filed Critical Heat Biologics Inc
Publication of SG10201913573UA publication Critical patent/SG10201913573UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10201913573UA 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins SG10201913573UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235727P 2015-10-01 2015-10-01
US201562263313P 2015-12-04 2015-12-04
US201662372574P 2016-08-09 2016-08-09

Publications (1)

Publication Number Publication Date
SG10201913573UA true SG10201913573UA (en) 2020-03-30

Family

ID=58424302

Family Applications (5)

Application Number Title Priority Date Filing Date
SG11201801984TA SG11201801984TA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913576RA SG10201913576RA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913591SA SG10201913591SA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913573UA SG10201913573UA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913597VA SG10201913597VA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SG11201801984TA SG11201801984TA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913576RA SG10201913576RA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
SG10201913591SA SG10201913591SA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913597VA SG10201913597VA (en) 2015-10-01 2016-09-30 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Country Status (17)

Country Link
US (13) US10183060B2 (en)
EP (2) EP4183451A1 (en)
JP (3) JP6981973B2 (en)
KR (1) KR20180051651A (en)
CN (3) CN116063567A (en)
AU (2) AU2016331076B2 (en)
BR (1) BR112018006578A2 (en)
CA (1) CA2999280A1 (en)
HK (1) HK1258835A1 (en)
IL (3) IL295423B2 (en)
MX (2) MX2018004022A (en)
PH (1) PH12018500694A1 (en)
RU (2) RU2022102624A (en)
SA (1) SA518391219B1 (en)
SG (5) SG11201801984TA (en)
UA (1) UA126549C2 (en)
WO (1) WO2017059168A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
BR112018000917A2 (en) 2015-07-16 2018-09-11 Bioxcel Therapeutics Inc innovative approach to cancer treatment through immunomodulation
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
LT3565579T (en) 2017-01-05 2023-09-11 Kahr Medical Ltd. A pd1-41bbl fusion protein and methods of use thereof
WO2018127916A1 (en) * 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
WO2018157163A1 (en) * 2017-02-27 2018-08-30 Shattuck Labs, Inc. Vsig8-based chimeric proteins
BR112019017713A2 (en) * 2017-02-27 2020-04-07 Shattuck Labs Inc chimeric csf1r-based proteins
US11332509B2 (en) * 2017-02-27 2022-05-17 Shattuck Labs, Inc. Methods of making and using extracellular domain-based chimeric proteins
AU2018237682A1 (en) * 2017-03-24 2019-11-14 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
KR20180120893A (en) * 2017-04-28 2018-11-07 재단법인 목암생명과학연구소 Fusion protein comprising pvr and 4-1bbl, and use thereof
CA3070299A1 (en) * 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
CN109646678A (en) * 2017-10-12 2019-04-19 中国科学院上海生命科学研究院 SUN2 albumen, its pharmaceutical applications and drug
CN108384795A (en) * 2017-10-13 2018-08-10 江苏西迪尔生物技术有限公司 Act on synthetic gene and verification method and the application of TME immune effector cells
EP3700938A1 (en) * 2017-10-26 2020-09-02 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. Novel recombinant fusion proteins, preparation and use thereof
AU2018365880A1 (en) * 2017-11-07 2020-05-28 The Board Of Regents Of The University Of Texas System Targeting LILRB4 with car-T or car-NK cells in the treatment of cancer
WO2019136316A1 (en) * 2018-01-04 2019-07-11 Washington University Compositions and methods for inhibition of alphavirus infection
EP3795585A4 (en) 2018-05-16 2022-03-16 Genome and Company Pharmaceutical composition for preventing or treating cancer comprising lrit2 inhibitor as active ingredient
CA3100349A1 (en) * 2018-05-17 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
KR20210025054A (en) 2018-06-21 2021-03-08 샤턱 랩스 인코포레이티드 Heterodimeric proteins and uses thereof
WO2020012486A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
JP2021531265A (en) * 2018-07-11 2021-11-18 カール メディカル リミテッド PD1-4-1BBL variant fusion protein and its usage
MX2021002002A (en) 2018-08-23 2021-05-31 Seagen Inc Anti-tigit antibodies.
JP2022512541A (en) * 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド Combination therapy including PD-1 chimeric protein
MX2021002289A (en) * 2018-08-29 2021-05-27 Shattuck Labs Inc Flt3l-based chimeric proteins.
JP2022512539A (en) * 2018-08-29 2022-02-07 シャタック ラボ，インコーポレイテッド Combination therapy
WO2020047322A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
CN109053902B (en) * 2018-09-11 2021-06-15 河南科技大学 Chimeric protein AQP4-CH2, preparation and application thereof
US20220025061A1 (en) * 2018-12-10 2022-01-27 Bioxcel Therapeutics, Inc. Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
KR20210107058A (en) * 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 Bifunctional Molecules Against Human PD-1
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
JP2022524178A (en) * 2019-01-07 2022-04-28 セルリス パルティシパソエス リミターダ How to Modulate Tumor Microenvironment with Bispecificity in Tandem Receptor CAR
KR20210113244A (en) * 2019-01-07 2021-09-15 샤턱 랩스 인코포레이티드 Heterodimeric Proteins to Regulate Gamma Delta T Cells
CN111606999B (en) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 Replicative oncolytic adenovirus with functions of activating immune co-stimulatory signaling pathway and blocking immune checkpoint and application thereof
JP2022522479A (en) * 2019-02-28 2022-04-19 シャタック ラボ，インコーポレイテッド Combination therapy
EP3969058A4 (en) * 2019-05-16 2023-06-28 Shattuck Labs, Inc. Nk cell-directed chimeric proteins
EP3986442A4 (en) * 2019-06-21 2023-10-25 Shattuck Labs, Inc. Chimeric protein expressing t-cells
KR20220044284A (en) * 2019-07-11 2022-04-07 카 메디컬 리미티드 Heterodimer and method of use thereof
US20220306715A1 (en) * 2019-08-30 2022-09-29 Shattuck Labs, Inc. Chimeric proteins in autoimmunity
CN112480237B (en) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 Fusion protein and preparation method and application thereof
CN110592172B (en) * 2019-10-29 2021-05-28 华中农业大学 Method and target for screening JEV resistance gene by using CRISPR/Cas9 knockout library technology
CN110964119A (en) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 Anti-malarial dimeric immunoadhesin, pharmaceutical composition and use
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
CN111826400A (en) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 Preparation method of bispecific antibody NK cell, cell and application thereof
CN111849913B (en) * 2020-07-31 2021-05-25 南京北恒生物科技有限公司 Engineered immune cells and uses thereof
US20230416333A1 (en) * 2020-10-26 2023-12-28 Shattuck Labs, Inc. Homodimeric and heterodimeric proteins comprising butyrophilin
KR20220124005A (en) * 2021-03-02 2022-09-13 주식회사 이뮤노로지컬디자이닝랩 Recombinant protein which induces cytotoxicity in CD30 expressing cell and the composition comprising the same for treating cancer
AU2022229900A1 (en) * 2021-03-05 2023-10-05 Shattuck Labs, Inc. Combination therapies with sirp alpha-based chimeric proteins
WO2022187583A1 (en) * 2021-03-05 2022-09-09 Shattuck Labs, Inc. Combination therapies with tim-3-based chimeric proteins
KR20220138909A (en) * 2021-04-06 2022-10-14 주식회사 이뮤노로지컬디자이닝랩 Chimeric antigen receptor specifically binding to CD47 and use thereof
WO2023004424A2 (en) * 2021-07-23 2023-01-26 University Of Southern California Genetically engineered multifunctional exosomes for immunotherapy
WO2023019251A1 (en) * 2021-08-12 2023-02-16 Baylor College Of Medicine Engineered soluble decoy receptors to enhance cancer immunotherapy
WO2023119295A1 (en) * 2021-12-23 2023-06-29 Kahr Medical Ltd. Lilrb polypeptides and uses thereof
WO2023141106A2 (en) * 2022-01-20 2023-07-27 Exocure Biosciences Inc. Recombinant cell line expressing membrane proteins and vesicles prepared therefrom
WO2024006931A1 (en) * 2022-07-01 2024-01-04 Fate Therapeutics, Inc. Enhancing effector cell durability and efficacy in adoptive cell therapies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
ATE365209T1 (en) 1992-05-14 2007-07-15 Baylor College Medicine MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE AND MOLECULAR SWITCH FOR GENE THERAPY
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
DE69632235T2 (en) 1995-10-18 2004-08-26 Akzo Nobel N.V. Newcastle disease viral vaccines combined
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
WO2001049318A1 (en) 2000-01-03 2001-07-12 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
ES2649037T3 (en) 2000-12-12 2018-01-09 Medimmune, Llc Molecules with prolonged half-lives, compositions and uses thereof
CA2466279A1 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP3020413A1 (en) * 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
JP4685764B2 (en) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション Modification of antibody FcRn binding affinity or serum half-life by mutagenesis
CN1902227A (en) * 2003-10-03 2007-01-24 布赖汉姆妇女医院 TIM-3 ligands and methods thereof
KR20050047030A (en) * 2003-11-13 2005-05-19 한미약품 주식회사 Igg fc fragment for a drug carrier and method for the preparation thereof
MXPA06014126A (en) * 2004-06-04 2007-07-18 Regeneron Pharma Methods of using il-1 antagonists to treat autoinflammatory disease.
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2006345852A (en) 2005-06-16 2006-12-28 Virxsys Corp Antibody conjugate
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP2027151A2 (en) 2006-05-15 2009-02-25 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
MX2008015524A (en) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function.
CA2656923A1 (en) * 2006-06-21 2007-12-27 Genentech, Inc. Crystal structures of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
CA2711938C (en) 2008-01-15 2019-11-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by cd47
US20090226435A1 (en) 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
KR101855381B1 (en) * 2008-04-09 2018-05-09 제넨테크, 인크. Novel compositions and methods for the treatment of immune related diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
AU2009269141B2 (en) 2008-06-30 2013-04-04 University Of Pennsylvania Fn14/TRAIL fusion proteins
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
MX338825B (en) * 2008-10-02 2016-05-03 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins.
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
JP2012512640A (en) * 2008-12-19 2012-06-07 ノバルティス アーゲー Soluble polypeptides for use in the treatment of autoimmune and inflammatory disorders
CN102421913A (en) 2009-03-13 2012-04-18 宾夕法尼亚大学董事会 Ox40/trail fusion proteins
CA2791383C (en) 2010-03-05 2022-09-20 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
EP2621514B1 (en) 2010-09-28 2016-09-21 KAHR Medical (2005) Ltd Compositions and methods for treatment of hematological malignancies
US9029315B2 (en) 2010-11-11 2015-05-12 The University Of Hong Kong Soluble PD-1 variants, fusion constructs, and uses thereof
WO2012142515A2 (en) * 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN102850458B (en) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 Novel recombined dual-function fusion protein and its preparation method and application
AU2012290342A1 (en) 2011-07-29 2014-01-30 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
CA2863818A1 (en) 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
EP3489254B9 (en) 2012-04-30 2022-12-21 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
US9745381B2 (en) 2012-05-18 2017-08-29 Scott & White Healthcare (Swh) Bispecific scFv immunofusion (BIf)
AU2013271515A1 (en) 2012-06-06 2015-01-15 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the Hippo pathway and uses thereof
CN112587658A (en) 2012-07-18 2021-04-02 博笛生物科技有限公司 Targeted immunotherapy for cancer
HUE058790T2 (en) 2012-12-17 2022-09-28 Pf Argentum Ip Holdings Llc Treatment of cd47+ disease cells with sirp alpha-fc fusions
EP2941438A1 (en) 2013-01-01 2015-11-11 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
WO2014121085A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for modulating regulatory and effector t cells
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
WO2014121099A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
HUE050787T2 (en) * 2013-02-26 2021-01-28 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
NZ711445A (en) 2013-03-12 2018-06-29 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
CN112457403B (en) * 2013-09-13 2022-11-29 广州百济神州生物制药有限公司 anti-PD 1 antibodies and their use as therapeutic and diagnostic agents
BR112016008039A2 (en) * 2013-10-15 2017-10-17 Novo Nordisk Healthcare Ag coagulation factor vii polypeptides
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
CA2934028A1 (en) * 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
BR112016013741A2 (en) * 2013-12-17 2017-10-03 Genentech Inc USES OF PD-1 AXIS LEADING ANTAGONISTS AND AN ANTI-CD20 ANTIBODY, AND KITS COMPRISING THEM
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
WO2015148416A1 (en) * 2014-03-24 2015-10-01 Deqiang Jing Novel recombinant bi-functional fusion proteins, preparation and use thereof
JP6666267B2 (en) 2014-05-29 2020-03-13 メディミューン，エルエルシー OX40L fusion proteins and uses thereof
WO2015200828A1 (en) 2014-06-27 2015-12-30 H. Lee Moffit Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
GB2532619A (en) 2014-08-08 2016-05-25 Alexo Therapeutics Int Sirp-Alpha Variant Constructs And Uses Thereof
HUE043038T2 (en) 2014-08-11 2019-07-29 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3643727A1 (en) 2014-08-15 2020-04-29 Merck Patent GmbH Sirp-alpha immunoglobulin fusion proteins
BR112017010198A2 (en) 2014-11-17 2017-12-26 Genentech Inc combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN107405398A (en) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 VSIG8 is identified as presumption VISTA acceptors and its to produce the purposes of VISTA/VSIG8 activators and antagonist
RU2017129236A (en) * 2015-01-26 2019-03-07 Макродженикс, Инк. MULTIValent MOLECULES CONTAINING DR5-BINDING DOMAINS
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
AU2016215175B2 (en) 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
WO2016187226A1 (en) 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Sirp polypeptide compositions and methods of use
PT3331902T (en) 2015-08-07 2021-07-26 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies

Also Published As

Publication number Publication date
BR112018006578A2 (en) 2018-12-26
HK1258835A1 (en) 2019-11-22
IL295423B1 (en) 2023-07-01
CA2999280A1 (en) 2017-04-06
JP2023112132A (en) 2023-08-10
US20200261537A1 (en) 2020-08-20
US20180326006A1 (en) 2018-11-15
AU2016331076A1 (en) 2018-04-05
RU2022102624A (en) 2022-03-10
US10543253B2 (en) 2020-01-28
KR20180051651A (en) 2018-05-16
US20180125935A1 (en) 2018-05-10
EP3356393A4 (en) 2019-08-07
IL303586A (en) 2023-08-01
CN108350055B (en) 2022-11-08
US20200246431A1 (en) 2020-08-06
US10493128B2 (en) 2019-12-03
JP2021168699A (en) 2021-10-28
US20180326008A1 (en) 2018-11-15
SG11201801984TA (en) 2018-04-27
US10086042B2 (en) 2018-10-02
US20170095531A1 (en) 2017-04-06
CN116063567A (en) 2023-05-05
UA126549C2 (en) 2022-11-02
IL258029B (en) 2022-09-01
SG10201913576RA (en) 2020-02-27
AU2021200367A1 (en) 2021-03-18
AU2016331076B2 (en) 2020-12-03
US10653748B2 (en) 2020-05-19
US10525102B2 (en) 2020-01-07
US10646545B2 (en) 2020-05-12
SA518391219B1 (en) 2022-11-30
US10183060B2 (en) 2019-01-22
US20180326007A1 (en) 2018-11-15
MX2022001299A (en) 2022-05-10
US10188701B2 (en) 2019-01-29
EP4183451A1 (en) 2023-05-24
CN116063566A (en) 2023-05-05
US11654180B2 (en) 2023-05-23
IL258029A (en) 2018-05-31
IL295423B2 (en) 2023-11-01
US10449233B2 (en) 2019-10-22
EP3356393A1 (en) 2018-08-08
US20190151413A1 (en) 2019-05-23
US11547742B1 (en) 2023-01-10
WO2017059168A1 (en) 2017-04-06
US10660936B2 (en) 2020-05-26
IL295423A (en) 2022-10-01
SG10201913591SA (en) 2020-02-27
US20200101136A1 (en) 2020-04-02
US20180326005A1 (en) 2018-11-15
RU2766200C1 (en) 2022-02-09
JP6981973B2 (en) 2021-12-17
AU2021200367B2 (en) 2024-05-02
US20180064787A1 (en) 2018-03-08
JP7303254B2 (en) 2023-07-04
PH12018500694A1 (en) 2018-10-01
JP2018529363A (en) 2018-10-11
US20180326004A1 (en) 2018-11-15
MX2018004022A (en) 2018-09-11
CN108350055A (en) 2018-07-31
SG10201913597VA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
HK1258835A1 (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
HK1259190A1 (en) Methods and compositions relating to chimeric antigen receptors
IL282168A (en) Factor viii chimeric proteins and uses thereof
HK1252643A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
ZA201704231B (en) Chimeric protein
HK1253306A1 (en) Anti-ntb-a antibodies and related compositions and methods
SI3240895T1 (en) Compositions and methods for protein glycosylation
GB201709537D0 (en) Fusion protein comprising three binding domains to 5ta and cd3
SG11201704010UA (en) Fibroin-derived protein composition
IL247632A0 (en) Methods and compositions for secretion of heterologous polypeptides
EP3256163A4 (en) Methods and compositions for modulating lilr proteins
IL257302B (en) Apoa-1 fusion polypeptides and related compositions and methods
HK1243107B (en) Chimeric protein